DUBLIN--(BUSINESS WIRE)--The "2nd Annual Real-World Data and Life Science Analytics Congress" conference has been added to ResearchAndMarkets.com's offering.
With the increasing recognition of real-world data opportunities and challenges within the pharmaceutical and biotech industry, life sciences organizations face clear decisions on how specifically to put resources into real-world evidence capacities. Real-World Evidence can possibly change the way life sciences associations use advancements to increase further clinical bits of knowledge and enable them and payers to collaborate like never before. After the successful inaugural, this year's congress will hold discussions on accelerating the adoption of Real-world Evidence within the industry while understanding the capabilities of newer technologies for evidence generation.
- Learn how the adoption of real-world evidence can be accelerated across pharmaceutical industry users
- Explore capabilities of using Artificial Intelligence & Machine Learning in taming scientific research users
- Understand the impact of innovative real-world evidence partnerships for better data
Sessions
- Adopting the Right Methodology for Real-World Evidence
- Achieving New Level of Quality Insights from Data
- Artificial Intelligence & Blockchain: Gamechanger in Real-World Evidence
Key Highlights
- Real-World Evidence Methodologies
- FDA's new strategic framework for the use of real-world evidence
- Applications of Artificial Intelligence & Blockchain for Real-World Data Analysis
- Evaluation of data sources for better patient outcomes
- Accelerating adoption of Real-world evidence in the pharmaceutical industry and elsewhere
Who Should Attend:
Chief executives, VPs, Directors, Global heads, Heads, Leaders, Senior Managers, Researchers, from Pharmaceutical and Biopharmaceutical companies working in the following departments:
- Real-World Evidence
- Health Economics & Outcomes Research
- Market Access
- Value Access
- Clinical Outcomes
- Clinical Development
- Center for Observational and Real-World Evidence
Agenda:
Day 1
- Registration 08:15 - 08:55
- Welcome note 08:55 - 09:00
- Opening Remarks from the Chairman 09:00 - 09:05
-
Keynote 09:05 - 09:15
- Shailendra Singh (Shelly), Chief Operating Officer, MarketsandMarkets
STRATEGIC FRAMEWORK & REGULATORY CONSIDERATIONS
-
Keynote Presentation: Leveraging RWE to gain, maintain and optimize market access across the globe 09:15 - 09:45
- Charles Makin, Global Head, Real World Evidence Strategy, Biogen
-
FDA's Real-World Evidence Program: Framework for Evaluating RWD/RWE for Use in Regulatory Decisions 09:45 - 10:15
- Nneka Onwudiwe, Founder and Chief Executive Officer, Pharmaceutical Economics Consultants of America
- Panel discussion: Pros & Cons of Real-World Evidence framework by FDA. Perspective from different stakeholders- providers & payers 10:15 - 10:45
- Morning Refreshments - One-to-One Networking Meetings - Networking break 11:15 - 12:05
-
Assessing the upcoming changes in the regulatory landscape in terms of Real-World Data 12:35 - 13:00
- Alex Mutebi, Director, Global Real World Evidence, Vertex Pharmaceuticals
- Lunch - One-to-One Networking Meetings - Networking break 13:35 - 14:45
Stream A: Achieving New Level of Quality Insights from Data
-
Treatments for Health Conditions with High Patient Heterogeneity: Can Real World Data Make Our Drug Development Programs Smarter? 14:45 - 15:15
- Vic Spain, Senior Real World Data Scientist, Genentech
- Senior Representative, Syneos Health 15:15 - 15:45
-
Evaluating the Strengths and Limitations of Real-World Data for Better Real-World Evidence Generation 15:45 - 16:15
- Susan Fish, Associate Director, Registries and Real-World Data, Celgene
- Evening Refreshments - One-to-One Networking Meetings 16:15 - 17:05
-
Impact of Real-World Evidence across the LifeCycle 17:05 - 17:35
- Marla Curran, Executive Director, Head of Biometrics & Medical Writing, Paratek Pharmaceuticals
- Drinks Reception & Networking 17:35 - 19:00
Stream B: Life Science Analytics
-
Advancing Commercial Analytics through Real-World Data 14:45 - 15:15
- Rachel Twardowski, Associate Director, Specialty Analytics, Takeda Pharmaceuticals
-
Presentation by 15:15 - 15:45
- Simon Andrews, Vice President, DRG Analytics, Decision Resources Group
-
Deriving value from Real-World Data with Artificial Intelligence & Machine Learning 15:45 - 16:15
- Jyotsna Kasturi, Associate Director, Real World Evidence Statistics, Teva Pharmaceuticals
- Evening Refreshments - One-to-One Networking Meetings 16:15 - 17:05
- Overcoming challenges of inter-linked data sources to generate essential evidence 17:05 - 17:35
- Drinks Reception & Networking 17:35 - 19:00
Day 2
- Registration 08:15 - 08:55
- Welcome note 08:55 - 09:00
- Opening Remarks from the Chairman 09:00 - 09:10
ADOPTION OF THE RIGHT METHODOLOGY FOR REAL-WORLD EVIDENCE
-
Keynote Presentation 09:10 - 09:40
- Jennifer L. Wong, Senior Director, Real World Evidence Strategy & Al, AstraZeneca
-
Accelerating RWE through Novel Data and Site Network Access 09:40 - 10:10
- Janak Joshi, SVP & Chief Technology Officer, LifeImage
-
Use case: Impact of innovative Real-World Evidence partnerships to get better data 10:10 - 10:40
- Brian Sweet, Executive Director, Oncology, Real World Evidence, Bristol-Myers Squibb
- Morning Refreshments - One-to-One Networking Meetings - Networking break 10:40 - 11:30
BREAKTHROUGH TO EXCELLENT DATA EVALUATION
-
Maximize the Influence of Real-World Evidence by Utilizing Available Data to Drive Life Science Innovation and Drug Development
- 11:30 - 12:00 Matthew A. Michela, President & CEO, LifeImage, Komodo Health
-
12:00 - 12:30 Senior Representative, Komodo Health
- Demonstrating Real-World Reliability to Support Fitness-for-Use
- 12:30 - 13:00 Nirosha Lederer, Managing Associate, Real World Evidence, Duke Margolis Center for Health Policy, Duke University
- Lunch - One-to-One Networking Meetings - Networking break 13:00 - 14:00
-
Using Real-World Data to Inform Early Disease Understanding 14:30 - 15:00
- Valerie (Hastings) Strezsak, Epidemiologist, Takeda Pharmaceuticals
- Presentation by 15:00 - 15:30 Sofia Iqbal Kring, Real World Evidence and Core Clinical Trials Manager, Novo Nordisk
- Closing remarks from the Chairman 15:30 - 15:35
For more information about this conference visit https://www.researchandmarkets.com/r/bu1xfq
